Transgene to Move Lung Cancer Drug Into Advanced Tests
This article is for subscribers only.
Transgene SA plans to start enrolling patients for advanced tests of its experimental lung cancer medicine as early as next summer after a mid-stage trial helped determine which people are most likely to respond. The shares gained the most in almost two years.
Preliminary results of an intermediate trial, released yesterday, suggests the drug known as TG4010 is well tolerated by non-small cell lung cancer sufferers and showed researchers how to refine the criteria used to select patients.